Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1954 1
1961 2
1962 3
1964 1
1965 4
1966 6
1968 4
1969 7
1970 4
1971 7
1972 6
1973 2
1974 8
1975 10
1976 4
1977 8
1978 8
1979 5
1980 10
1981 9
1982 16
1983 21
1984 13
1985 17
1986 15
1987 19
1988 22
1989 32
1990 33
1991 41
1992 56
1993 46
1994 45
1995 39
1996 40
1997 58
1998 64
1999 60
2000 61
2001 65
2002 73
2003 68
2004 74
2005 102
2006 95
2007 117
2008 96
2009 91
2010 110
2011 130
2012 138
2013 147
2014 121
2015 143
2016 138
2017 164
2018 171
2019 168
2020 193
2021 118
Text availability
Article attribute
Article type
Publication date

Search Results

3,038 results
Results by year
Filters applied: . Clear all
Page 1
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Matsuyama Y, Unno M; Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). Motoi F, et al. Among authors: wada k. Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. doi: 10.1093/jjco/hyy190. Jpn J Clin Oncol. 2019. PMID: 30608598 Clinical Trial.
[COVID-19 and stroke].
Wada K, Hashimoto Y, Nakajima M, Ueda M. Wada K, et al. Rinsho Shinkeigaku. 2020 Dec 26;60(12):822-839. doi: 10.5692/clinicalneurol.cn-001529. Epub 2020 Nov 20. Rinsho Shinkeigaku. 2020. PMID: 33229838 Review. Japanese.
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Morizane C, et al. Among authors: wada k. Ann Oncol. 2019 Dec 1;30(12):1950-1958. doi: 10.1093/annonc/mdz402. Ann Oncol. 2019. PMID: 31566666 Free article. Clinical Trial.
Real-World Effectiveness of Ramelteon and Suvorexant for Delirium Prevention in 948 Patients With Delirium Risk Factors.
Hatta K, Kishi Y, Wada K, Takeuchi T, Hashimoto N, Suda K, Taira T, Tsuchida K, Ohmori T, Akizuki N, Nishio Y, Nakanishi Y, Usui C, Kurata A, Horikawa N, Eguchi H, Ito S, Muto H, Nakamura H, Uchimura N. Hatta K, et al. Among authors: wada k. J Clin Psychiatry. 2019 Dec 17;81(1):19m12865. doi: 10.4088/JCP.19m12865. J Clin Psychiatry. 2019. PMID: 31851436 Free article. Clinical Trial.
Nasal function and CPAP compliance.
Inoue A, Chiba S, Matsuura K, Osafune H, Capasso R, Wada K. Inoue A, et al. Among authors: wada k. Auris Nasus Larynx. 2019 Aug;46(4):548-558. doi: 10.1016/j.anl.2018.11.006. Epub 2018 Dec 8. Auris Nasus Larynx. 2019. PMID: 30538069
Tobacco Smoking and Mortality in Asia: A Pooled Meta-analysis.
Yang JJ, Yu D, Wen W, Shu XO, Saito E, Rahman S, Gupta PC, He J, Tsugane S, Xiang YB, Gao YT, Koh WP, Tamakoshi A, Irie F, Sadakane A, Tsuji I, Kanemura S, Matsuo K, Nagata C, Chen CJ, Yuan JM, Shin MH, Park SK, Pan WH, Qiao YL, Pednekar MS, Gu D, Sawada N, Li HL, Gao J, Cai H, Grant E, Tomata Y, Sugawara Y, Ito H, Wada K, Shen CY, Wang R, Ahn YO, You SL, Yoo KY, Ashan H, Chia KS, Boffetta P, Inoue M, Kang D, Potter JD, Zheng W. Yang JJ, et al. Among authors: wada k. JAMA Netw Open. 2019 Mar 1;2(3):e191474. doi: 10.1001/jamanetworkopen.2019.1474. JAMA Netw Open. 2019. PMID: 30924901 Free PMC article.
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Kessoku T, et al. Among authors: wada k. Lancet Gastroenterol Hepatol. 2020 Nov;5(11):996-1007. doi: 10.1016/S2468-1253(20)30216-8. Epub 2020 Aug 15. Lancet Gastroenterol Hepatol. 2020. PMID: 32805205 Clinical Trial.
Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
Minakawa EN, Popiel HA, Tada M, Takahashi T, Yamane H, Saitoh Y, Takahashi Y, Ozawa D, Takeda A, Takeuchi T, Okamoto Y, Yamamoto K, Suzuki M, Fujita H, Ito C, Yagihara H, Saito Y, Watase K, Adachi H, Katsuno M, Mochizuki H, Shiraki K, Sobue G, Toda T, Wada K, Onodera O, Nagai Y. Minakawa EN, et al. Among authors: wada k. Brain. 2020 Jun 1;143(6):1811-1825. doi: 10.1093/brain/awaa115. Brain. 2020. PMID: 32436573
3,038 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page